Loading...
Loading...
Alkermes
ALKS today announced that the United States Patent and
Trademark Office (USPTO) has issued a Notice of Allowance for U.S.
Patent Application 14/032,736, entitled “Prodrugs of fumarates and their
use in treating various diseases.” The allowed composition of matter
claims will cover Alkermes' MMF prodrug, ALKS 8700, a proprietary,
small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of
multiple sclerosis. The Notice of Allowance resulted from a prioritized
examination granted by the USPTO, and the allowed claims are directed
toward a novel MMF prodrug that is designed to rapidly and efficiently
convert to MMF in the body. Alkermes expects to file an Investigational
New Drug (IND) application with the U.S. Food and Drug Administration
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in